Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025
Surveillance for adverse events following use of live attenuated chikungunya vaccine, United States, 2024, and the associated public health response in 2024 and 2025.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hills Susan L, Sutter Rebekah A, Miller Elaine R, Asturias Edwin J, Chen Lin H, Bell Beth P, McNeil Michael M, Rakickas Jeffrey, Wharton Melinda, Meyer Sarah, Staples J Erin
Аннотация
A live attenuated chikungunya vaccine (IXCHIQ) received licensure in the United States (US) for ≥ 18-year-olds in November 2023. Post-licensure safety surveillance identified 28 adverse events in 2024 among US persons, including six neurological or cardiac serious adverse events (SAEs) in males ≥ 65 years. In early 2025, providers were alerted, a precaution for older persons was issued and vaccine guidance was updated. In May, following 11 additional SAEs reported outside the US, use in older persons was temporarily paused until 6 August 2025.
Предметные рубрики MeSH
HumansChikungunya FeverUnited StatesMaleVaccines, AttenuatedFemaleChikungunya virusAgedAdverse Drug Reaction Reporting SystemsAdolescentProduct Surveillance, PostmarketingMiddle AgedAdultViral VaccinesAged, 80 and overPublic HealthPopulation SurveillanceYoung AdultDrug-Related Side Effects and Adverse Reactions